Ratings by Leerink (Joseph Schwartz)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/18/2026 | uniQure BV | QURE | Maintain | Outperform (N/A) |
|
Details | ||
| 6/16/2026 | Edgewise Therapeutics | EWTX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/16/2026 | Edgewise Therapeutics | EWTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/18/2026 | Design Therapeutics Inc | DSGN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/15/2026 | Atrium Therapeutics | RNA | New Coverage | Outperform (N/A) |
13.27 (12.81) |
-3.47% | Details | |
| 5/14/2026 | AN2 Therapeutics | ANTX | Upgrade | Outperform (Market Perform) |
4.31 (4.98) |
15.55% | Details | |
| 4/6/2026 | Satellos Bioscience Inc. | MSLE | New Coverage | Outperform (N/A) |
5.87 (5.67) |
-3.41% | Details | |
| 4/2/2026 | Ultragenyx Pharma | RARE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/27/2026 | Monopar Therapeutics | MNPR | Maintain | Outperform (N/A) |
|
Details | ||
| 3/25/2026 | Maze Therapeutics | MAZE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/25/2026 | Kalvista Pharmaceuticals Inc | KALV | Maintain | Outperform (N/A) |
|
Details | ||
| 3/19/2026 | Mereo BipPharma Group | MREO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/12/2026 | Ultragenyx Pharma | RARE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/9/2026 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/2/2026 | uniQure BV | QURE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2026 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 2/24/2026 | Gossamer Bio Inc. | GOSS | Downgrade | Market Perform (Outperform) |
2.13 (0.17) |
-92.02% | Details | |
| 1/5/2026 | Larimar Therapeutics | LRMR | New Coverage | Outperform (N/A) |
3.47 (3.68) |
6.05% | Details | |
| 12/31/2025 | Ultragenyx Pharma | RARE | Maintain | Outperform (N/A) |
|
Details | ||
| 12/29/2025 | Ultragenyx Pharma | RARE | Maintain | Outperform (N/A) |
|
Details | ||
| 12/29/2025 | Mereo BipPharma Group | MREO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/29/2025 | Ultragenyx Pharma | RARE | Maintain | Outperform (N/A) |
|
Details | ||
| 12/29/2025 | Amicus Therapeutics | FOLD | Downgrade | Market Perform (Outperform) |
14.25 (14.49) |
1.68% | Details | |
| 12/18/2025 | Maze Therapeutics | MAZE | Maintain | Outperform (N/A) |
|
Details | ||
| 12/3/2025 | Pharvaris B.V. | PHVS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/3/2025 | Spruce Biosciences, Inc. | SPRB | Upgrade | Outperform (Market Perform) |
89.20 (52.14) |
-41.55% | Details | |
| 12/3/2025 | Design Therapeutics Inc | DSGN | Upgrade | Outperform (Market Perform) |
8.94 (13.74) |
53.69% | Details | |
| 12/3/2025 | Aurinia Pharmaceuticals | AUPH | Downgrade | Market Perform (Outperform) |
15.91 (17.88) |
12.38% | Details | |
| 12/3/2025 | BioMarin Pharmaceutical Inc. | BMRN | Downgrade | Market Perform (Outperform) |
53.89 (56.50) |
4.84% | Details | |
| 11/10/2025 | uniQure BV | QURE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2025 | Monopar Therapeutics | MNPR | New Coverage | Outperform (N/A) |
80.95 (81.77) |
1.01% | Details | |
| 10/27/2025 | Avidity Biosciences | RNA | Downgrade | Market Perform (Outperform) |
49.15 (13.27) |
-73% | Details | |
| 10/21/2025 | Spruce Biosciences, Inc. | SPRB | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/24/2025 | uniQure BV | QURE | Maintain | Outperform (N/A) |
|
Details | ||
| 9/11/2025 | Maze Therapeutics | MAZE | Maintain | Underperform (N/A) |
|
Details | ||
| 7/10/2025 | Kalvista Pharmaceuticals Inc | KALV | Maintain | Outperform (N/A) |
|
Details | ||
| 7/7/2025 | Kalvista Pharmaceuticals Inc | KALV | Maintain | Outperform (N/A) |
|
Details | ||
| 6/30/2025 | Aurinia Pharmaceuticals | AUPH | Maintain | Outperform (N/A) |
|
Details | ||
| 5/12/2025 | Aurinia Pharmaceuticals | AUPH | Maintain | Outperform (N/A) |
|
Details | ||
| 4/30/2025 | Regulus Therapeutics | RGLS | Downgrade | Market Perform (Outperform) |
3.37 (8.16) |
142.14% | Details | |
| 2/25/2025 | Maze Therapeutics | MAZE | New Coverage | Outperform (N/A) |
10.82 (26.41) |
144.09% | Details | |
| 11/6/2024 | Ultragenyx Pharma | RARE | Maintain | Outperform (N/A) |
|
Details | ||
| 10/30/2024 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/4/2024 | Ultragenyx Pharma | RARE | Maintain | Outperform (N/A) |
|
Details | ||
| 9/19/2024 | Edgewise Therapeutics | EWTX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/6/2024 | Kalvista Pharmaceuticals Inc | KALV | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2024 | AN2 Therapeutics | ANTX | Downgrade | Market Perform (Outperform) |
2.64 (4.31) |
63.26% | Details | |
| 7/3/2024 | AN2 Therapeutics | ANTX | Upgrade | Outperform (Market Perform) |
2.13 (4.98) |
133.8% | Details | |
| 6/24/2024 | Solid Biosciences | SLDB | Upgrade | Outperform (Market Perform) |
6.46 (8.79) |
36.07% | Details | |
| 5/16/2024 | Ultragenyx Pharma | RARE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/18/2024 | Regulus Therapeutics | RGLS | New Coverage | Outperform (N/A) |
2.11 (3.37) |
59.72% | Details | |
| 3/14/2024 | Spruce Biosciences, Inc. | SPRB | Downgrade | Market Perform (Outperform) |
5.19 (89.20) |
1618.69% | Details | |
| 2/13/2024 | Kalvista Pharmaceuticals Inc | KALV | Maintain | Outperform (N/A) |
|
Details | ||
| 2/13/2024 | AN2 Therapeutics | ANTX | Downgrade | Market Perform (Outperform) |
20.00 (4.98) |
-75.1% | Details | |
| 2/9/2024 | Synlogic Inc. | SYBX | Downgrade | Market Perform (Outperform) |
3.45 (0.56) |
-83.77% | Details | |
| 11/9/2023 | Avidity Biosciences | RNA | Maintain | Outperform (N/A) |
|
Details | ||
| 9/8/2023 | Spruce Biosciences, Inc. | SPRB | Upgrade | Outperform (Market Perform) |
2.27 (52.14) |
2196.92% | Details | |
| 8/15/2023 | Design Therapeutics Inc | DSGN | Downgrade | Market Perform (Outperform) |
7.33 (8.94) |
21.96% | Details | |
| 6/13/2023 | Chinook Therapeutics | KDNY | Downgrade | Market Perform (Outperform) |
37.98 (40.39) |
6.35% | Details | |
| 12/27/2022 | Applied Molecular Transport | AMTI | Downgrade | Market Perform (Outperform) |
1.03 (0.26) |
-74.76% | Details | |
| 10/17/2022 | Solid Biosciences | SLDB | Downgrade | Market Perform (Outperform) |
0.46 (8.79) |
1810.87% | Details | |
| 9/13/2022 | Pharvaris B.V. | PHVS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/23/2022 | Pharvaris B.V. | PHVS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/5/2022 | ChemoCentryx | CCXI | Downgrade | Market Perform (Outperform) |
50.43 (10.42) |
-79.34% | Details | |
| 5/23/2022 | Chinook Therapeutics | KDNY | Maintain | Outperform (N/A) |
|
Details | ||
| 5/19/2022 | Applied Molecular Transport | AMTI | Maintain | Outperform (N/A) |
|
Details | ||
| 4/6/2022 | Imara Inc. | IMRA | Downgrade | Market Perform (Outperform) |
1.63 (17.59) |
979.14% | Details | |
| 3/17/2022 | Synlogic Inc. | SYBX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2022 | Aurinia Pharmaceuticals | AUPH | Maintain | Outperform (N/A) |
|
Details | ||
| 1/14/2022 | Amicus Therapeutics | FOLD | Upgrade | Outperform (Market Perform) |
10.13 (14.25) |
40.67% | Details | |
| 11/16/2021 | Spruce Biosciences, Inc. | SPRB | Downgrade | Market Perform (Outperform) |
4.47 (52.14) |
1066.44% | Details | |
| 11/3/2021 | Aurinia Pharmaceuticals | AUPH | Maintain | Outperform (N/A) |
|
Details | ||
| 10/11/2021 | ChemoCentryx | CCXI | Upgrade | Outperform (Market Perform) |
38.41 (10.42) |
-72.87% | Details | |
| 10/11/2021 | DICE Therapeutics | DICE | New Coverage | Outperform (N/A) |
26.49 (47.55) |
79.5% | Details | |
| 6/14/2021 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2021 | ChemoCentryx | CCXI | Downgrade | Market Perform (Outperform) |
27.49 (10.42) |
-62.1% | Details | |
| 4/20/2021 | Design Therapeutics Inc | DSGN | New Coverage | Outperform (N/A) |
23.00 (13.74) |
-40.26% | Details | |
| 3/22/2021 | Amicus Therapeutics | FOLD | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/16/2021 | Solid Biosciences | SLDB | Upgrade | Outperform (Market Perform) |
9.51 (8.79) |
-7.57% | Details | |
| 3/2/2021 | Pharvaris B.V. | PHVS | New Coverage | Outperform (N/A) |
39.23 (33.19) |
-15.4% | Details | |
| 2/22/2021 | Applied Molecular Transport | AMTI | Maintain | Outperform (N/A) |
|
Details | ||
| 2/16/2021 | Ultragenyx Pharma | RARE | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2021 | Millendo Therapeutics Inc. | MLND | Downgrade | Market Perform (Outperform) |
2.06 (1.06) |
-48.54% | Details | |
| 11/6/2020 | Inflarx NV | IFRX | Upgrade | Outperform (Market Perform) |
3.98 (0.99) |
-75.13% | Details | |
| 10/29/2020 | ChemoCentryx | CCXI | Maintain | Outperform (N/A) |
|
Details | ||
| 10/7/2020 | Chinook Therapeutics | KDNY | New Coverage | Outperform (N/A) |
14.77 (40.39) |
173.46% | Details | |
| 8/19/2020 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/5/2020 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/30/2020 | uniQure BV | QURE | Maintain | Outperform (N/A) |
|
Details | ||
| 7/27/2020 | Solid Biosciences | SLDB | Downgrade | Market Perform (Outperform) |
2.85 (8.79) |
208.42% | Details | |
| 7/7/2020 | Avidity Biosciences | RNA | New Coverage | Outperform (N/A) |
27.59 (49.15) |
78.14% | Details | |
| 6/30/2020 | Applied Molecular Transport | AMTI | New Coverage | Outperform (N/A) |
25.80 (0.26) |
-98.99% | Details | |
| 6/12/2020 | Imara Inc. | IMRA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/12/2020 | Crinetics | CRNX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/20/2020 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 4/6/2020 | Imara Inc. | IMRA | New Coverage | Outperform (N/A) |
15.75 (17.59) |
11.68% | Details | |
| 4/2/2020 | Kalvista Pharmaceuticals Inc | KALV | New Coverage | Outperform (N/A) |
6.75 (27.00) |
300% | Details | |
| 4/2/2020 | ChemoCentryx | CCXI | New Coverage | Outperform (N/A) |
38.58 (10.42) |
-72.99% | Details | |
| 3/3/2020 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/4/2019 | Audentes Therapeutics | BOLD | Downgrade | Market Perform (Outperform) |
28.61 (2.60) |
-90.91% | Details | |
| 11/26/2019 | The Medicines Company | MDCO | Downgrade | Market Perform (Outperform) |
68.55 (84.90) |
23.85% | Details | |
| 10/18/2019 | Achillion Pharmaceuticals | ACHN | Downgrade | Market Perform (Outperform) |
6.27 (0.79) |
-87.4% | Details | |
| 9/3/2019 | The Medicines Company | MDCO | Maintain | Outperform (N/A) |
|
Details | ||
| 8/22/2019 | Retrophin | RTRX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/19/2019 | Solid Biosciences | SLDB | Upgrade | Outperform (Market Perform) |
8.81 (8.79) |
-0.23% | Details | |
| 8/2/2019 | Ultragenyx Pharma | RARE | Maintain | Outperform (N/A) |
|
Details | ||
| 6/5/2019 | Inflarx NV | IFRX | Downgrade | Market Perform (Outperform) |
37.29 (1.93) |
-94.82% | Details | |
| 5/28/2019 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/5/2019 | Gossamer Bio Inc. | GOSS | New Coverage | Outperform (N/A) |
23.00 (2.13) |
-90.74% | Details | |
| 3/5/2019 | Nightstar Therapeutics | NITE | Downgrade | Market Perform (Outperform) |
15.16 (36.36) |
139.84% | Details | |
| 2/26/2019 | Clementia Pharmaceuticals Inc. | CMTA | Downgrade | Market Perform (Outperform) |
14.94 (26.35) |
76.37% | Details | |
| 2/14/2019 | ChemoCentryx | CCXI | New Coverage | Outperform (N/A) |
10.92 (10.42) |
-4.58% | Details | |
| 2/7/2019 | Solid Biosciences | SLDB | Downgrade | Market Perform (Outperform) |
22.34 (8.81) |
-60.56% | Details | |
| 2/7/2019 | Zafgen | ZFGN | Upgrade | Outperform (Market Perform) |
4.56 (0.99) |
-78.29% | Details | |
| 1/24/2019 | Ascendis Pharma | ASND | Upgrade | Outperform (Market Perform) |
73.65 (238.59) |
223.95% | Details | |
| 12/13/2018 | Millendo Therapeutics Inc. | MLND | New Coverage | Outperform (N/A) |
10.56 (1.06) |
-89.96% | Details | |
| 11/15/2018 | uniQure BV | QURE | Maintain | Outperform (N/A) |
|
Details | ||
| 10/24/2018 | Clementia Pharmaceuticals Inc. | CMTA | Maintain | Outperform (N/A) |
|
Details | ||
| 9/7/2018 | Nightstar Therapeutics | NITE | Maintain | Outperform (N/A) |
|
Details | ||
| 8/13/2018 | Crinetics | CRNX | New Coverage | Outperform (N/A) |
29.84 (35.91) |
20.34% | Details |
